Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
J Surg Res. 2012 Dec;178(2):974-81. doi: 10.1016/j.jss.2012.06.061. Epub 2012 Jul 11.
Cotreatment with regulatory T cells (T(reg)) and conventional allogeneic bone marrow transplantation (BMT) successfully induced durable chimerism and tolerance to nonvascularized skin allografts without cytoreductive conditioning in mice. We sought to determine whether T(reg) treatment combined with vascularized BMT (VBMT) could create mixed chimerism and induce tolerance to vascularized composite allografts (VCAs) without cytoreductive conditioning in rats.
Recipient Lewis rats treated (day 0) with or without naturally sorted T(reg) (3 × 10(6)) from Lewis rat spleen and lymph nodes received costimulation blockade (anti-CD154 monoclonal antibody, days 0 and 1 and CTLA-4 immunoglobin, days 2, 4, and 6), rapamycin (days -1, 0, and 2), and concurrent transplantation of fully mismatched allogeneic donor VCAs (day 0) from the Brown Norway rat hindlimb containing VBMT. The mixed chimerism level was assessed monthly using flow cytometry. Survival of VCAs and occurrence of graft-versus-host disease were assessed clinically and histologically.
The combination of T(reg) and VBMT treatment led to long-term multilineage hematopoietic mixed chimerism (12-18%) and long-term donor-specific tolerance to VCAs (89% acceptance rate). Neither stable mixed chimerism nor VCA acceptance was observed in recipients without T(reg) treatment. Graft-versus-host disease did not occur in the VBMT recipients.
Cotreatment with T(reg) and VBMT created stable mixed chimerism and induced long-term donor-specific tolerance to VCAs without requiring cytoreductive conditioning. This noncytoreductive T(reg)-VBMT protocol has potential for clinical application in VCAs.
在小鼠中,共培养调节性 T 细胞(Treg)和常规同种异体骨髓移植(BMT)成功地诱导了持久的嵌合体,并在没有细胞减少预处理的情况下耐受非血管化皮肤同种异体移植物。我们试图确定 Treg 治疗联合血管化 BMT(VBMT)是否可以在没有细胞减少预处理的情况下,在大鼠中创建混合嵌合体并诱导对血管化复合移植物(VCAs)的耐受。
接受 Lewis 大鼠(第 0 天)接受或不接受来自 Lewis 大鼠脾脏和淋巴结的天然分选 Treg(3×106),并用共刺激阻断(抗-CD154 单克隆抗体,第 0 天和第 1 天和 CTLA-4 免疫球蛋白,第 2、4 和 6 天)、雷帕霉素(第-1、0 和 2 天)和来自 Brown Norway 大鼠后肢的完全不匹配同种异体供体 VCAs(第 0 天)的同时移植。使用流式细胞术每月评估混合嵌合体水平。临床和组织学评估 VCAs 的存活和移植物抗宿主病的发生。
Treg 和 VBMT 联合治疗导致长期多谱系造血混合嵌合体(12-18%)和对 VCAs 的长期供体特异性耐受(接受率 89%)。没有 Treg 治疗的受者既没有稳定的混合嵌合体,也没有接受 VCA。VBMT 受者未发生移植物抗宿主病。
Treg 和 VBMT 的共同治疗在不进行细胞减少预处理的情况下,产生了稳定的混合嵌合体,并诱导了对 VCAs 的长期供体特异性耐受。这种非细胞减少的 Treg-VBMT 方案有可能在 VCAs 中得到临床应用。